→ PTOBF

Attorney Docket No.: Inventors:

Serial No.:

Filing Date:

Page 4

ISPH-0518 Baker et al. 09/695,451

October 24, 2000

## REMARKS

Claims 1, 2, and 5-15 are pending in this application. Reconsideration is respectfully requested in view of the following remarks.

At the outset, Applicants thank Examiner Schultz for the courtesy of a telephone interview on February 9, 2004. In Applicants' response to the original restriction requirement, claim 1 was amended to recite SEQ ID NO:1 as the target sequence. In response to the Office Action mailed 7/16/03, Applicants amended the claims to recite regions of the target sequence, i.e., nucleobases 727-868 and 899-1310 of SEQ ID NO:1.

The Notice of Non-Responsive Amendment indicates that the limitation to these target regions within SEQ ID NO:1 was not responsive. However, following the telephone interview, it was agreed that these two regions could be searched. Accordingly, Applicants elect an antisense compound 8 to 30 nucleobases in length targeted to nucleobases 727 through 868 or nucleobases 899

→ PTOBF

Attorney Docket No.: ISPH-0518

Inventors:

Baker et al.

Serial No.:

09/695,451

Filing Date:

October 24, 2000

Page 5

through 1310 of a nucleic acid molecule encoding TNFR1 (SEQ ID NO:1), wherein said compound specifically inhibits the expression of TNFR1.

Respectfully submitted,

Janessylusti

Jane Massey Licata Registration No. 32,257

Date: February 10, 2004

Licata & Tyrrell P.C. 66 Main Street Marlton, NJ 08053

856-810-1515